Spyre Therapeutics (SYRE) took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing. But analysts are far more interested in Spyre's inflammatory bowel disease drugs. These conditions include ulcerative colitis and Crohn's disease. "Even excluding all non-UC (ulcerative colitis) indications, our PT (price target) would remain at ~$115, well above current trading levels,"…
Spyre Therapeutics Plunges; Why Analysts Aren't Sweating
Kaynak: Yahoo Finance
İlgili Haberler
Global
Stocks making the biggest moves after hours: Gap, Workday, Autodesk and more
CNBC Finance · 1 saat önce
Global
Fed Chairman Kevin Warsh delivers his key Jackson Hole speech Friday. Here's what to expect
CNBC Finance · 3 saat önce
Global
Anthropic Bet Tens of Billions on AMD. One Month Later, It Signed a $45 Billion Nvidia-Powered Lease
Yahoo Finance · 4 saat önce
Global
Citi Says It’s Time to Buy the Dip on Oracle Stock. Here’s Why
Yahoo Finance · 5 saat önce
Global
Nvidia's Latest $20 Billion Investment May Be a Huge Surprise to Some Investors
Yahoo Finance · 5 saat önce
Yorumlar (0)
Giriş yaparak yorum yazabilirsin.
İlk yorumu sen yaz.